# Immunai

> Immunai is a New York biotechnology company that builds single-cell maps of the human immune system and applies machine learning and laboratory validation to drug discovery and clinical development. Its customers are pharmaceutical companies and research partners seeking better targets, biomarkers and patient selection. AMICA, its annotated immune atlas, underpins collaborations with AstraZeneca, Bristol Myers Squibb, Teva and Boehringer Ingelheim.

- **Founded:** 2018
- **Headquarters:** New York, United States
- **Founders:** Noam Solomon (Co-founder and CEO), Luis Voloch (Co-founder and founding CTO), Ansuman Satpathy (Scientific co-founder), Danny Wells (Scientific co-founder), Dan Littman (Founding scientist)
- **Products:** AMICA, ImmunoDynamics Engine, AMICA-OS, Target discovery, Clinical trial optimization
- **Notable:** Built AMICA, an annotated multiomic immune atlas combining proprietary, partner and public data., Acquired Dropprint Genomics in March 2021 and Nebion in July 2021 to deepen single-cell software and data curation., Announced a $215 million Series B in October 2021.

## Products & services

- **AMICA** — Annotated Multiomic Immune Cell Atlas: a harmonized data foundation combining proprietary, partner and public single-cell immune data with clinical annotations.
- **ImmunoDynamics Engine** — Machine learning and analytical framework that links immune features to mechanisms, treatment response and potential biomarkers.
- **AMICA-OS** — AI operating system combining AMICA, models and lab validation for target discovery and clinical development decisions.
- **Target discovery** — Find and validate disease-linked immune targets with single-cell data and functional experiments.
- **Clinical trial optimization** — Analyze mechanisms, dose, patient subgroups and biomarkers for pharma trial programs.
- **Academic data-for-data collaboration** — Selected non-commercial academic centers provide approved patient cohorts and metadata; Immunai funds sequencing and returns data and annotations while enriching its atlas.

## Achievements

- Built AMICA, an annotated multiomic immune atlas combining proprietary, partner and public data.
- Acquired Dropprint Genomics in March 2021 and Nebion in July 2021 to deepen single-cell software and data curation.
- Announced a $215 million Series B in October 2021.
- Expanded its AstraZeneca relationship from oncology trials into an inflammatory bowel disease target agreement.
- Signed a 2026 Boehringer Ingelheim discovery program spanning oncology and autoimmune disease.

## Latest updates

- **2026-07** — Published team videos on AMICA pipelines, computational biology and pharma collaboration.
- **2026-06** — Announced an initial Boehringer Ingelheim discovery program valued at up to $15 million through 2027.
- **2026-05** — AstraZeneca expanded its oncology collaboration through 2027; Immunai is eligible for up to $37.5 million across 2026-27.
- **2026-01** — Announced Bristol Myers Squibb collaboration for clinical development analysis using AMICA-OS.
- **2025-10** — Announced an AstraZeneca agreement on an Immunai-identified inflammatory bowel disease target, with up to $85 million in potential consideration.

## Links

- Website: https://www.immunai.com/
- LinkedIn: https://www.linkedin.com/company/immunai
- Twitter/X: https://x.com/Immunaitech

---

Profile page: https://yespress.io/immunai
Published by YesPress — https://yespress.io
Last updated: 2026-09-29